Multimodal AI Beats Oncotype DX — A New Era for Breast Cancer Recurrence Prediction | Reading Breast Cancer Diagnosis with AI, Vol. 3 2026-04-29 At SABCS 2025, multimodal AI (ICM+ model) outperforms Oncotype DX for 15-year recurrence prediction (C-index 0.733 vs 0.631). Final volume of our series.
AI Triage Cuts Radiologist Workload by 63% — A Partially Autonomous Workflow Demonstrated by AITIC | Reading Breast Cancer Diagnosis with AI, Vol. 2 2026-04-28 Spain’s AITIC trial (Nature Medicine 2026, n=31,301): partially autonomous AI workflow cuts radiologist workload 63.6%, lifts detection 15.2%. Vol. 2.
What MASAI Answered — Has AI Mammography Surpassed Radiologists? | Reading Breast Cancer Diagnosis with AI, Vol. 1 2026-04-26 Sweden’s MASAI trial (Lancet 2026, n>105,000) shows AI mammography cuts interval cancers by 12% and lifts sensitivity to 80.5%. Vol. 1 of our series.
Complete Series | From Beginner to Expert: Bispecific Antibody Drug Series — Full Index and Final Overview 2026-04-19 Across 12 deep-dives we have rebuilt how to think about bispecific antibodies—from molecular geometry to clini […]
From Beginner to Expert | Bispecific Antibody Drug Series B6: The Technological Evolution and Historical Path of Improvement in Bispecific Antibody Drugs 2026-04-18 Bispecific antibody drugs are now discussed as one of the important modalities in cancer therapy. Bispecific a […]
From Beginner to Expert | Bispecific Antibody Drug Series A6: What Is Likely to Grow Next? A Map of Next-Generation Bispecific Antibody Drugs 2026-04-16 Bispecific antibody drugs are already beginning to establish a distinct clinical presence, especially in hemat […]
From Beginner to Expert | Bispecific Antibody Drug Series B5: How Should We Think About Clinical Development Strategy and Indication Expansion? 2026-04-14 Bispecific antibody drugs are a modality in which theoretical appeal alone is not enough; where and how clinic […]
From Beginner to Expert | Bispecific Antibody Drug Series A5: Where Do Bispecific Antibody Drugs Sit Within the Overall Landscape of Cancer Therapy? 2026-04-12 Bispecific antibody drugs have gained a strong presence within cancer therapy over the past several years. Bis […]
From Beginner to Expert | Bispecific Antibody Drug Series B4: How Should We Think About Toxicity, PK/PD, and Development Bottlenecks? 2026-04-07 Bispecific antibody drugs are a modality that often looks highly attractive in theory. Bispecific antibody dru […]
From Beginner to Expert | Bispecific Antibody Drug Series A4: Why Do Adverse Effects Occur? Understanding the Balance Between Efficacy and Safety 2026-04-06 Bispecific antibody drugs are a modality with enormous promise in cancer therapy. Bispecific antibody drugs ar […]
